$329 Million is the total value of Tamarack Advisers, LP's 22 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 59.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $45,726,000 | +35.0% | 3,925,000 | +10.6% | 13.90% | +3.4% |
| MDT | Buy | MEDTRONIC PLCequity | $41,168,000 | +29.1% | 420,000 | +20.0% | 12.52% | -1.1% |
| BIO | Buy | BIO-RAD LABORATORIES-Aequity | $30,931,000 | +55.7% | 100,000 | +53.8% | 9.40% | +19.2% |
| PCRX | Buy | PACIRA BIOSCIENCES INCequity | $27,044,000 | +122.1% | 625,000 | +95.3% | 8.22% | +70.1% |
| SRCL | Sell | STERICYCLE INCequity | $22,373,000 | -19.4% | 475,000 | -6.9% | 6.80% | -38.3% |
| ATRC | Buy | ATRICURE INCequity | $21,195,000 | +86.1% | 675,000 | +58.8% | 6.44% | +42.6% |
| LNTH | Sell | LANTHEUS HOLDINGS INCequity | $20,104,000 | -13.6% | 730,000 | -23.2% | 6.11% | -33.8% |
| DGX | New | QUEST DIAGNOSTICS INCequity | $19,357,000 | – | 188,900 | +100.0% | 5.89% | – |
| PTLA | Sell | PORTOLA PHARMACEUTICALS INCequity | $14,419,000 | -42.7% | 555,000 | -23.4% | 4.38% | -56.1% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INCequity | $14,016,000 | +2.9% | 5,475,000 | +3.3% | 4.26% | -21.2% |
| HOLX | Buy | HOLOGIC INCequity | $13,019,000 | +19.6% | 275,000 | +22.2% | 3.96% | -8.4% |
| HAE | New | HAEMONETICS CORP/MASSequity | $12,057,000 | – | 100,000 | +100.0% | 3.67% | – |
| ZBH | New | ZIMMER BIOMET HOLDINGS INCequity | $10,863,000 | – | 90,000 | +100.0% | 3.30% | – |
| New | NOVOCURE LTDequity | $9,636,000 | – | 150,000 | +100.0% | 2.93% | – | |
| CMD | Buy | CANTEL MEDICAL CORPequity | $9,113,000 | +354.1% | 115,000 | +283.3% | 2.77% | +247.7% |
| CORV | Buy | CORREVIO PHARMA CORPequity | $7,437,000 | -1.9% | 3,350,000 | +39.6% | 2.26% | -24.9% |
| ISEE | New | IVERIC BIO INCequity | $3,720,000 | – | 3,000,000 | +100.0% | 1.13% | – |
| STRM | Buy | STREAMLINE HEALTH SOLUTIONSequity | $3,276,000 | +60.0% | 2,100,000 | +7.7% | 1.00% | +22.5% |
| NVRO | Sell | NEVRO CORPequity | $3,154,000 | -68.5% | 50,000 | -68.8% | 0.96% | -75.8% |
| SPY US 07/19/19 P295put | $264,000 | -37.1% | 4,000 | 0.0% | 0.08% | -52.1% | ||
| New | AMGN US 07/19/19 P170put | $11,000 | – | 250 | +100.0% | 0.00% | – | |
| Exit | MDCO US 04/18/19 P22put | $0 | – | -1,714 | -100.0% | -0.01% | – | |
| VSI | Exit | VITAMIN SHOPPE INCequity | $0 | – | -13,158 | -100.0% | -0.04% | – |
| TMO | Exit | THERMO FISHER SCIENTIFIC INCequity | $0 | – | -10,000 | -100.0% | -1.09% | – |
| OBLN | Exit | OBALON THERAPEUTICS INCequity | $0 | – | -2,044,440 | -100.0% | -1.17% | – |
| OPHT | Exit | OPHTHOTECH CORPequity | $0 | – | -3,000,000 | -100.0% | -1.68% | – |
| SCI | Exit | SERVICE CORP INTERNATIONALequity | $0 | – | -120,000 | -100.0% | -1.91% | – |
| ALKS | Exit | ALKERMES PLCequity | $0 | – | -140,000 | -100.0% | -2.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.